Open Access
Original Research Article
J Oral Med Oral Surg
Volume 27, Number 4, 2021
Article Number 47
Number of page(s) 10
Published online 15 October 2021
  1. Bink K. Analysis of denosumab on skeletal-related events in patients with advanced breast cancer. Clin J Oncol Nurs 2015;19:E108–E114. [CrossRef] [PubMed] [Google Scholar]
  2. Macedo F, et al. Bone metastases: an overview. Oncol Rev 2017:11. DOI: 10.4081/oncol.2017.321. [Google Scholar]
  3. Domschke C, Schuetz F. Side effects of bone-targeted therapies in advanced breast cancer. Breast Care 2014;9:8. [CrossRef] [Google Scholar]
  4. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 2012;66:1139–1146. [CrossRef] [PubMed] [Google Scholar]
  5. Henry DH, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–1132. [CrossRef] [PubMed] [Google Scholar]
  6. Nicolatou-Galitis O, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:117–135. [Google Scholar]
  7. Stopeck AT, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132–5139. [CrossRef] [PubMed] [Google Scholar]
  8. Lipton A, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082–3092. [CrossRef] [PubMed] [Google Scholar]
  9. Hayes AR, Brungs D, Pavlakis N. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysis. PLOS ONE 2018;13:e0191455. [CrossRef] [PubMed] [Google Scholar]
  10. Kulkarni AG, Patel A. Denosumab: a potential new treatment option for recurrent aneurysmal bone cyst of the spine. SICOT-J 2019;5:10. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  11. de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR. The anti-tumor effect of RANKL inhibition in malignant solid tumors − a systematic review. Cancer Treatment Rev 2018;62:18–28. [CrossRef] [Google Scholar]
  12. Uday S, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018;103:596–603. [CrossRef] [PubMed] [Google Scholar]
  13. Saad F, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341–1347. [CrossRef] [PubMed] [Google Scholar]
  14. Murphy J, Mannion CJ. Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis. Br J Oral Maxillofac Surg 2020;58:619–624. [CrossRef] [PubMed] [Google Scholar]
  15. Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in2015. Osteoporosis Int. 2016;27:853–859. [CrossRef] [PubMed] [Google Scholar]
  16. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment Rev. 2018;69:177–187. [CrossRef] [Google Scholar]
  17. Pazianas M. Osteonecrosis of the Jaw and the Role of Macrophages. JNCI J Natl Cancer Inst 2011;103:232–240. [CrossRef] [PubMed] [Google Scholar]
  18. Boquete-Castro A, Gómez-Moreno J, Calvo-Guirado L, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 2016;27:367–375. [CrossRef] [PubMed] [Google Scholar]
  19. Di Fede O, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. BioMed Res Int 2018;1–10. [Google Scholar]
  20. Ruggiero SL, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofacial Surg 2014;72:1938–1956. [CrossRef] [Google Scholar]
  21. Coleman R, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;31:1650–1663. [CrossRef] [Google Scholar]
  22. Lettres aux professionnels de santé_Recommandations sur la prise en charge bucco-dentaire des patients traités par bisphosphonates_AFSSAPS2007. Accessed: Jan. 14, 2021. [Online] aux-professionnels-de-sante/Recommandations-sur-la-prise-en-charge-bucco-dentaire-des-patients-traites-par-bisphosphonates [Google Scholar]
  23. Société Française de Stomatologie, Chirurgie Maxillo-Faciale et Chirurgie Orale, Ostéonécrose des mâchoires en oromaxillofaciale et traitements médicamenteux à risque (antirésorbeurs osseux, antiangiogéniques)_Recommandations de Bonnes Pratiques-2013. Accessed: Jan. 14, 2021. [Online]édicaments-antirésorbeurs.VF-juillet-2013.pdf [Google Scholar]
  24. Confrère C. Lettre aux professionnels de santé “Denosumab 120mg (XGEVA®): Mise à jour des informations de sécurité d'emploi pour minimiser les risques d'ostéonécrose de la mâchoire et d'hypocalcémie, ”_ANSM2014. professionnels-de-sante [Google Scholar]
  25. Owosho AA, et al. Medication-related osteonecrosis of the jaw: an update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125:440–445. [Google Scholar]
  26. Dimopoulos MA, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117–120. [CrossRef] [PubMed] [Google Scholar]
  27. Okuma S, Matsuda Y, Nariai Y, Karino M, Suzuki R, Kanno T. A retrospective observational study of risk factors for denosumab-related osteonecrosis of the jaw in patients with bone metastases from solid cancers. Cancers 2020;12:1209. [CrossRef] [Google Scholar]
  28. Egloff-Juras C, et al. Denosumab-related osteonecrosis of the jaw: a retrospective study. J Oral Pathol Med 2018;47:66–70. [CrossRef] [PubMed] [Google Scholar]
  29. Khan AA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Mineral Res 2015;30:3–23. [CrossRef] [Google Scholar]
  30. Ohga N, Sato J, Asaka T, Morimoto M, Yamazaki Y, Kitagawa Y. Successful conservative treatment of jaw osteonecrosis caused by denosumab in patients with multiple bone metastasis. J Oral Sci 2018;60:159–162. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.